Mesoblast LtdHere is the public summary page for Mesoblast Ltd. Please login to see the complete information for Mesoblast Ltd including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Mesoblast Ltd stacks up relative to its peers. |
Darwin Score | -8 |
Ticker | MSB |
Latest Price | 2.35 AUD as of close on 01-Aug-2025 |
3 Month price range | 1.57 to 1.88 AUD |
Market Capitalisation | 2.05Bn AUD |
Country | Australia |
Economic Sector | Health Care |
Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
Industry | Biotechnology |
Sub-Industry | Biotechnology |
Description | Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and GrĂ¼nenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. See More ... |
Company URL | https://www.mesoblast.com |
See Darwins Full Analysis for Mesoblast Ltd |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Mesoblast Ltd. Further information and full detail is available when you login.
TMA Part | Focus of Analysis | TMA Score |
---|---|---|
Price | Analysis of performance, trend, RSI, OBV and moving averages | -16 |
Sentiment | News and Candle Patterns. | 0 |
Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | -1 |
Flow | Institutional, Fund and Insider buying and selling. | 0 |
Models | Forecast models. | +9 |
Peer Comparison
There are 11 peers of Mesoblast Ltd.
Asset Name | Industry Group | Asset Score |
---|---|---|
Argenica Therapeutics Ltd (AGN) | Biotechnology | +7 |
BTC Health Ltd (BTC) | Biotechnology | +27 |
CSL Ltd (CSL) | Biotechnology | +12 |
Clinuvel Pharmaceuticals Ltd (CUV) | Biotechnology | -19 |
Imugene Ltd (IMU) | Biotechnology | -10 |
Opthea Ltd (OPT) | Biotechnology | -13 |
PYC Therapeutics Ltd (PYC) | Biotechnology | +27 |
Paradigm Biopharmaceuticals Ltd (PAR) | Biotechnology | +13 |
Polynovo Ltd (PNV) | Biotechnology | -2 |
Race Oncology Ltd (RAC) | Biotechnology | 0 |
Telix Pharmaceuticals Ltd (TLX) | Biotechnology | +1 |